Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00525472 | Colorectum | MSS | regulation of peptidase activity | 130/3467 | 461/18723 | 1.81e-07 | 8.13e-06 | 130 |
GO:00071732 | Colorectum | MSS | epidermal growth factor receptor signaling pathway | 43/3467 | 108/18723 | 1.92e-07 | 8.31e-06 | 43 |
GO:00381272 | Colorectum | MSS | ERBB signaling pathway | 46/3467 | 121/18723 | 3.63e-07 | 1.45e-05 | 46 |
GO:00420602 | Colorectum | MSS | wound healing | 119/3467 | 422/18723 | 5.93e-07 | 2.24e-05 | 119 |
GO:20012342 | Colorectum | MSS | negative regulation of apoptotic signaling pathway | 72/3467 | 224/18723 | 6.17e-07 | 2.29e-05 | 72 |
GO:00510992 | Colorectum | MSS | positive regulation of binding | 59/3467 | 173/18723 | 7.11e-07 | 2.53e-05 | 59 |
GO:00341092 | Colorectum | MSS | homotypic cell-cell adhesion | 36/3467 | 90/18723 | 1.62e-06 | 5.32e-05 | 36 |
GO:20012432 | Colorectum | MSS | negative regulation of intrinsic apoptotic signaling pathway | 38/3467 | 98/18723 | 2.09e-06 | 6.41e-05 | 38 |
GO:20001162 | Colorectum | MSS | regulation of cysteine-type endopeptidase activity | 72/3467 | 235/18723 | 4.39e-06 | 1.24e-04 | 72 |
GO:00525482 | Colorectum | MSS | regulation of endopeptidase activity | 117/3467 | 432/18723 | 6.25e-06 | 1.65e-04 | 117 |
GO:00432812 | Colorectum | MSS | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 65/3467 | 209/18723 | 7.29e-06 | 1.86e-04 | 65 |
GO:00108222 | Colorectum | MSS | positive regulation of mitochondrion organization | 30/3467 | 74/18723 | 8.51e-06 | 2.11e-04 | 30 |
GO:00086372 | Colorectum | MSS | apoptotic mitochondrial changes | 39/3467 | 107/18723 | 8.92e-06 | 2.19e-04 | 39 |
GO:00458612 | Colorectum | MSS | negative regulation of proteolysis | 97/3467 | 351/18723 | 1.57e-05 | 3.54e-04 | 97 |
GO:00018362 | Colorectum | MSS | release of cytochrome c from mitochondria | 25/3467 | 59/18723 | 1.91e-05 | 4.13e-04 | 25 |
GO:00508782 | Colorectum | MSS | regulation of body fluid levels | 99/3467 | 379/18723 | 1.40e-04 | 2.07e-03 | 99 |
GO:19011841 | Colorectum | MSS | regulation of ERBB signaling pathway | 28/3467 | 79/18723 | 2.71e-04 | 3.63e-03 | 28 |
GO:00457852 | Colorectum | MSS | positive regulation of cell adhesion | 110/3467 | 437/18723 | 2.94e-04 | 3.87e-03 | 110 |
GO:00420581 | Colorectum | MSS | regulation of epidermal growth factor receptor signaling pathway | 26/3467 | 73/18723 | 4.05e-04 | 4.99e-03 | 26 |
GO:00511012 | Colorectum | MSS | regulation of DNA binding | 37/3467 | 118/18723 | 5.29e-04 | 5.99e-03 | 37 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PLAUR | SNV | Missense_Mutation | rs750492027 | c.829N>A | p.Ala277Thr | p.A277T | Q03405 | protein_coding | tolerated(0.19) | benign(0.018) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | | c.198N>G | p.Ser66Arg | p.S66R | Q03405 | protein_coding | deleterious(0) | benign(0.284) | TCGA-AR-A24Q-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
PLAUR | insertion | In_Frame_Ins | novel | c.389_390insTCCCCTGGCCCCCATAGGGCGTCCAAAGGATGA | p.Gly130_Arg131insProLeuAlaProIleGlyArgProLysAspAsp | p.G130_R131insPLAPIGRPKDD | Q03405 | protein_coding | | | TCGA-A8-A09A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
PLAUR | SNV | Missense_Mutation | | c.346G>A | p.Glu116Lys | p.E116K | Q03405 | protein_coding | deleterious(0.01) | probably_damaging(0.987) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
PLAUR | SNV | Missense_Mutation | rs756038834 | c.814N>A | p.Ala272Thr | p.A272T | Q03405 | protein_coding | tolerated(0.3) | benign(0.042) | TCGA-NH-A5IV-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | | c.118G>T | p.Ala40Ser | p.A40S | Q03405 | protein_coding | tolerated(0.21) | benign(0.028) | TCGA-AF-4110-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | I/II | Chemotherapy | oxaliplatin | SD |
PLAUR | SNV | Missense_Mutation | novel | c.979N>A | p.Leu327Met | p.L327M | Q03405 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.533) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | novel | c.389N>A | p.Gly130Asp | p.G130D | Q03405 | protein_coding | deleterious(0.01) | benign(0.264) | TCGA-AJ-A23O-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | novel | c.668N>T | p.Ser223Ile | p.S223I | Q03405 | protein_coding | deleterious(0) | probably_damaging(0.959) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
PLAUR | SNV | Missense_Mutation | | c.252N>T | p.Lys84Asn | p.K84N | Q03405 | protein_coding | deleterious(0.03) | benign(0.213) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | ADENOVIRAL VECTOR | | 12955075 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | UROKINASE | UROKINASE | |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | RECOMBINANT INTERFERON GAMMA | | 8049441 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | G-CSF | FILGRASTIM | 15747404 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | MCP-2 | | 12138365 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | DIPHTHERIA TOXIN | | 11959893 |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | Ruxolitinib | RUXOLITINIB | |
5329 | PLAUR | DRUGGABLE GENOME, ENZYME, CELL SURFACE | | PHORBOL MYRISTATE ACETATE | | 9531044 |